RUFFATTI, AMELIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 12.929
AS - Asia 1.769
EU - Europa 1.442
Continente sconosciuto - Info sul continente non disponibili 8
OC - Oceania 7
AF - Africa 2
SA - Sud America 2
Totale 16.159
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 12.916
CN - Cina 972
SG - Singapore 598
FI - Finlandia 307
DE - Germania 251
IT - Italia 241
SE - Svezia 181
UA - Ucraina 162
VN - Vietnam 142
FR - Francia 135
GB - Regno Unito 95
JP - Giappone 25
NL - Olanda 20
IE - Irlanda 16
IN - India 14
HK - Hong Kong 9
EU - Europa 8
CA - Canada 7
BE - Belgio 6
AU - Australia 5
CZ - Repubblica Ceca 5
GR - Grecia 5
MX - Messico 5
RU - Federazione Russa 5
ES - Italia 4
ID - Indonesia 3
BR - Brasile 2
IL - Israele 2
IR - Iran 2
NZ - Nuova Zelanda 2
PL - Polonia 2
BG - Bulgaria 1
CH - Svizzera 1
DK - Danimarca 1
GT - Guatemala 1
HU - Ungheria 1
MA - Marocco 1
NG - Nigeria 1
PT - Portogallo 1
RO - Romania 1
SA - Arabia Saudita 1
SK - Slovacchia (Repubblica Slovacca) 1
TH - Thailandia 1
Totale 16.159
Salva come PNG Salva come JPEG
Città #
Fairfield 2.095
Woodbridge 1.312
Chandler 1.034
Houston 1.031
Ashburn 871
Jacksonville 757
Wilmington 743
Ann Arbor 739
Seattle 736
Cambridge 671
Singapore 471
Princeton 340
Boardman 321
Santa Clara 230
Beijing 215
San Diego 211
Nanjing 157
Des Moines 145
Dong Ket 142
Medford 142
Roxbury 121
Helsinki 106
Padova 62
Dearborn 58
Guangzhou 50
Hebei 47
Nanchang 46
Hefei 41
Jinan 36
Jiaxing 35
Shenyang 35
Changsha 30
New York 24
Norwalk 24
Kunming 22
Redwood City 20
London 18
Los Angeles 18
Ogden 15
Dublin 14
Tianjin 14
Kharkiv 13
Milan 13
Zhengzhou 13
Falls Church 10
Mito 10
Shanghai 10
Frankfurt am Main 9
Tsukuba 9
Wuhan 8
Falkenstein 7
Hong Kong 7
Nürnberg 7
Verona 7
Washington 7
Hanover 6
Indiana 6
Kilburn 6
Munich 6
Ningbo 6
Rockville 6
Tappahannock 6
Brussels 5
Fuzhou 5
Naples 5
New Bedfont 5
Prescot 5
Pune 5
Allauch 4
Borås 4
Brno 4
Chengdu 4
Chongqing 4
Dallas 4
Harbin 4
Orange 4
Rapino 4
Rome 4
Auburn Hills 3
Detroit 3
Genoa 3
Groningen 3
Haikou 3
Hangzhou 3
Puglianello 3
Quzhou 3
Shaoxing 3
Simi Valley 3
Southwark 3
Stockholm 3
Sydney 3
Taiyuan 3
Taizhou 3
Tokyo 3
Toronto 3
Wandsworth 3
Amsterdam 2
Bertinoro 2
Bussero 2
Castelfranco Emilia 2
Totale 13.503
Salva come PNG Salva come JPEG
Nome #
Erosive osteoarthritis, psoriatic arthritis and pseudogout; a casual association? 166
Plasma exchange effectively removes 52- and 60-kDa anti-Ro/SSA and anti-La/SSB antibodies in pregnant women with congenital heart block. 142
The efficacy of adalimumab in psoriatic arthritis concomitant to overlapping primary biliary cholangitis and primary sclerosing cholangitis: a case report 140
Evidence of complement activation in the thrombotic small vessels of a patient with catastrophic antiphospholipid syndrome treated with eculizumab 139
Plasma exchange for the management of the catastrophic antiphospholipid syndrome: importance of the type of fluid replacement. 137
Antibody profile and clinical course in primary anti phospholipid syndrome with pregnancy morbidity 133
Pregnancy and foetal outcomes following anti-tumor necrosis factor alpha therapy: A prospective multicentre study 132
Antibodies to Domain I of β2-Glycoprotein I are in Close Relation to Patients Risk Categories in Antiphospholipid Syndrome (APS) 131
Laboratory testing for antiphospholipid syndrome 131
Diagnosis and therapy of antiphospholipid syndrome 128
The clinical relevance of early anti-adalimumab antibodies detection in rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis: A prospective multicentre study 127
Circulating β2 glycoprotein I-IgG anti-β2 glycoprotein I immunocomplexes in patients with definite Antiphospholipid Syndrome. 120
Influence of different IgG anticardiolipin antibody cut-off values on antiphospholipid syndrome classification 118
Laboratory and clinical features of pregnant women with antiphospholipid syndrome and neonatal outcome. 117
Interpretation of laboratory data and need for reference laboratories. 117
Catastrophic antiphospholipid syndrome: Lessons from 14 cases successfully treated in a single center. A narrative report 115
An observational multicentre study on the efficacy and safety of assisted reproductive technologies in women with rheumatic diseases. 115
Increased apoptosis in circulating lymphocyte cultures of anti-RNA polymerase III positive patients with systemic sclerosis. 114
APS - Diagnostics and challenges for the future 113
Incidence of a first thromboembolic event in carriers of isolated lupus anticoagulant 110
Additional Treatments for High-Risk Obstetric Antiphospholipid Syndrome: a Comprehensive Review 110
Plasma exchange in a patient with primary antiphospholipid syndrome undergoing kidney transplantation 109
Clinical course of high-risk patients diagnosed with antiphospholipid syndrome. 108
A combination therapy protocol of plasmapheresis, intravenous immunoglobulins and betamethasone to treat anti-Ro/La-related congenital atrioventricular block. A case series and review of the literature. 107
A contribution to detection of anticardiolipin and anti-β2glycoprotein I antibodies: Comparison between a home-made ELISA and a fluorescence enzyme immunoassay. 107
Nuclear membrane-staining antinuclear antibody in patients with primary biliary cirrhosis. 107
Use of a new silica clotting time for diagnosing lupus anticoagulant in patients who meet the clinical criteria for antiphospholipid syndrome 106
Hypertension negatively affects the pregnancy outcome in patients with antiphospholipid syndrome. 106
The European Registry on Obstetric Antiphospholipid Syndrome (EUROAPS): A survey of 247 consecutive cases 106
Clinical and laboratory characteristics of isolated lupus anticoagulants 106
Antibodies to Domain 4/5 (Dm4/5) of β2-Glycoprotein 1 (β2GP1) in different antiphospholipid (aPL) antibody profiles 106
An analysis of experimental conditions influencing the anti-beta2-glycoprotein I ELISA assay results. 105
Antiphospholipid syndrome: critical analysis of the diagnostic path 105
The clinical performance of a chemiluminescent immunoassay in detecting anti-cardiolipin and anti-β2 glycoprotein i antibodies. A comparison with a homemade ELISA method 104
Lupus anticoagulant identifies two distinct groups of patients with different antibody patterns 104
A catastrophic antiphospholipid syndrome: the importance of high levels of warfarin anticoagulation. 103
Are biological drugs safe in pregnancy? 102
Relationship between antiphosphatidylserine/prothrombin and conventional antiphospholipid antibodies in primary antiphospholipid syndrome. 101
Early phenotypic activation of circulating helper memory T cells in scleroderma: correlation with disease activity 100
Correct laboratory approach to APS diagnosis and monitoring 99
Circulating microparticles in pregnant patients with primary anti-phospholipid syndrome: an exploratory study 99
Antiplatelet glycoprotein autoantibodies in patients with autoimmune diseases with and without thrombocytopenia. 98
Parotid, breast, and fascial involvement in a patient who fulfilled the ACR criteria for Churg-Strauss syndrome. 98
The clinical relevance of the IgM isotype of antiphospholipid antibodies in the vascular antiphospholipid syndrome 97
Anti-double-stranded DNA antibodies in the healthy elderly: prevalence andcharacteristics 97
Antiphosphatidylserine/prothrombin antibodies in primary antiphospholipid syndrome. 97
The association between circulating antibodies against domain I of beta2-glycoprotein I and thrombosis: an international multicenter study 96
A combination therapy to treat second-degree anti-ro/la-related congenital heart block. A strategy to avoid stable third-degree heart block? 96
Biological and clinical relevance of anti-prothrombin antibodies. 96
The clinical significance of autoantibodies directed against prothrombin in primary antiphospholipid syndrome. 96
IgA anticardiolipin and IgA anti-β2 glycoprotein I antibody positivity determined by fluorescence enzyme immunoassay in primary antiphospholipid syndrome. 96
100 years of Aspirin in the rheumatic diseases 95
Pregnancy, cytokines, and disease activity in systemic lupus erythematosus. 95
Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome 94
Antiphospholipid syndrome classification criteria: comments on the letter of Swadzba and Musial 93
Systemic sclerosis and aortic valve stenosis: therapeutic implications in two cases of aortic valve replacement 93
Antiphospholipid syndrome and right atrial mass 93
Confirmation of the initial antiphospholipid antibody positivity depends on antiphospholipid antibody profile 93
Prevalenza e significato clinico degli anticorpi anti-catepsina G nella sclerosi sistemica. 92
Recovery from catastrophic antiphospholipid syndrome by a plasma exchange procedure: Report of four cases and review of the literature 92
Failure of intravenous immunoglobulin to prevent congenital heart block: Findings of a multicenter, prospective, observational study. 91
Antiphospholipid syndrome: antibodies to Domain 1 of β2-glycoprotein 1 correctly classify patients at risk 91
Accelerated atherosclerosis in the aortic arch and cerebral ischemia in a patient with primary antiphospholipid syndrome 90
Apheresis and intravenous immunoglobulins used in addition to conventional therapy to treat high-risk pregnant antiphospholipid antibody syndrome patients. A prospective study 90
Anti-beta(2)-glycoprotein I ELISA assay: The influence of different antigen preparations 89
AUTOIMMUNE DISORDERS IN LOCALIZED SCLERODERMA 89
Treatment of 139 pregnancies in antiphospholipid-positive women not fulfilling criteria for antiphospholipid syndrome: a retrospective study. 89
Upgrading Therapy Strategy Improves Pregnancy Outcome in Antiphospholipid Syndrome: A Cohort Management Study 89
Low titer, isolated anti Ro/SSA 60 kd antibodies is correlated with positive pregnancy outcomes in women at risk of congenital heart block 88
Congenital heart block not associated with anti-Ro/La antibodies: comparison with anti-Ro/La-positive cases. 87
Antiphospholipid antibodies (aPL) in systemic lupus erythematosus. Are theyspecific tools for the diagnosis of aPL syndrome? 86
Detection of lupus anticoagulant in the era of direct oral anticoagulants 86
Some patients with antiphospholipid syndrome express hitherto undescribed antibodies to cardiolipin-binding proteins 85
Patients with primary antiphospholipid antibody syndrome and without associated vascular risk factors present a normal endothelial function. 85
Secondary prevention in thrombotic antiphospholipid syndrome. 85
Fibrinolytic pattern in recurrent spontaneous abortions: no relationship between hypofibrinolysis and anti-phospholipid antibodies. 84
Refractory obstetrical antiphospholipid syndrome: Features, treatment and outcome in a European multicenter retrospective study 84
“Disease knowledge index” and perspectives on reproductive issues: A nationwide study on 398 women with autoimmune rheumatic diseases 84
Short and long-term outcomes of children with autoimmune congenital heart block treated with a combined maternal-neonatal therapy. A comparison study 84
Plasma exchange and immunoadsorption effectively remove antiphospholipid antibodies in pregnant patients with antiphospholipid syndrome. 83
Anti-thyroid microsomal antibody in synovial fluid as a revealing feature of seronegative autoimmune thyroiditis 83
Therapeutic apheresis during pregnancy: A single center experience 83
La terapia dell'artrite reumatoide mediante levamisolo. 82
Inherited thrombophilia in women with poor aPL-related obstetric history: prevalence and outcomes. Survey of 208 cases from the European Registry on Obstetric Antiphospholipid Syndrome cohort 82
Laboratory classification categories and pregnancy outcome in patients with primary antiphospholipid syndrome prescribed antithrombotic therapy 81
Bedside diagnosis of two major clinical phenotypes of hypertensive disorders of pregnancy 81
Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study. 81
Long-term use of hydroxychloroquine reduces antiphospholipid antibodies levels in patients with primary antiphospholipid syndrome 80
Antiphospholipid antibodies in mixed connective tissue disease 79
Antiphospholipid antibody profile based obstetric outcomes of primary antiphospholipid syndrome: The PREGNANTS study 79
Plasma exchange in the management of high risk pregnant patients with primary antiphospholipid syndrome. A report of 9 cases and a review of the literature. 78
Platelet and endothelial activation in catastrophic and quiescent antiphospholipid syndrome. 78
Ferritin in the antiphospholipid syndrome and its catastrophic variant (cAPS) 78
Anti-SSA/Ro-related congenital heart block in two family members of different generations: Comment on the article by Clancy et al. 78
The efficacy of hydroxychloroquine for obstetrical outcome in anti-phospholipid syndrome: Data from a European multicenter retrospective study 78
Efficacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies: An international and collaborative meta-analysis 77
Maternal autoantibody profiles at risk for autoimmune congenital heart block: a prospective study in high-risk patients 76
Overview of the 8th meeting of the European Forum on antiphospholipid antibodies. 75
In vitro effect of anti-β2 Glycoprotein I antibodies on P-selectin expression, a marker of platelet activation 75
ANTICARDIOLIPIN ANTIBODIES AND ANTIPHOSPHOLIPID SYNDROME IN CHRONIC DISCOID LUPUS-ERYTHEMATOSUS 75
Totale 9.870
Salva come PNG Salva come JPEG
Categoria #
all - tutte 58.461
article - articoli 56.342
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 1.588
Totale 116.391
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20202.261 0 0 0 0 0 288 469 444 374 321 162 203
2020/20212.296 103 242 65 187 83 212 69 246 332 186 266 305
2021/20222.632 73 340 301 194 99 158 97 288 128 62 295 597
2022/20232.069 492 223 20 250 342 268 9 129 204 15 90 27
2023/2024916 42 150 125 74 68 87 47 43 30 24 112 114
2024/20251.391 22 295 247 165 559 103 0 0 0 0 0 0
Totale 16.290